Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13246140 | 0.87 | CYP2C19 (0.41) | CYP2C19PDE10A | |
| SCHEMBL3107419 | 0.87 | CYP2C19 (0.39) | CYP2C19KEAP1NFE2L2PDE10AHSP90AA1 | |
| SCHEMBL3111451 | 0.86 | PDE10A (0.48) | CYP2C19KEAP1NFE2L2CYP1A2PDE10A | |
| SCHEMBL4129860 | 0.79 | CYP2C19 (0.61) | CYP2C19KEAP1NFE2L2HSP90AA1ALDH1A1 | |
| SCHEMBL2455910 | 0.77 | GPR119 (0.41) | CYP2C19PDE10A | |
| SCHEMBL3120326 | 0.77 | PDE10A (0.46) | PDE10ARORC | |
| SCHEMBL3339311 | 0.71 | CYP2C19 (0.47) | CYP2C19KEAP1NFE2L2HSP90AA1ALDH1A1 | |
| SCHEMBL3115630 | 0.68 | — | — | |
| SCHEMBL9659996 | 0.68 | CREBBP (0.46) | CYP2C19GPBAR1KCNH2ALDH1A1HPGD | |
| SCHEMBL3341305 | 0.68 | CYP2C19 (0.47) | CYP2C19KEAP1NFE2L2CYP1A2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179173-A1 | SUBSTITUTED FUSED PYRIMIDINES AS ANTAGONISTS OF GPR105 ACTIVITY | MERCK FROSST CANADA LTD. (CA) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179173-A1 | SUBSTITUTED FUSED PYRIMIDINES AS ANTAGONISTS OF GPR105 ACTIVITY | GPR119, GPR35, GPR55 | CYP2C19 2584/4885KEAP1 3400/4885NFE2L2 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.